Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 241-248 |
| Number of pages | 8 |
| Journal | Breast Cancer Research and Treatment |
| Volume | 144 |
| Issue number | 4 |
| Early online date | 13 Feb 2014 |
| DOIs | |
| Publication status | Published - 1 Apr 2014 |
Fingerprint
Keywords
- [18F]FDG
- glucose transport
- PI3/AKT
- trastuzumab
Cite this
Early changes in [18F] FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions : Role of the Akt-pathway, glucose transport and HIF-1α. / Fleming, Ian Neil; Andriu, Alexandra; Smith, Timothy Andrew Davies.
In: Breast Cancer Research and Treatment, Vol. 144, No. 4, 01.04.2014, p. 241-248.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Early changes in [18F] FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions
T2 - Role of the Akt-pathway, glucose transport and HIF-1α
AU - Fleming, Ian Neil
AU - Andriu, Alexandra
AU - Smith, Timothy Andrew Davies
N1 - Acknowledgment The work was funded by the University of Aberdeen and Friends of Anchor. We thank Dr Iain Brown, University of Aberdeen, for the generous gift of the anti-pHER2 antibody.
PY - 2014/4/1
Y1 - 2014/4/1
N2 - HER-2 overexpression does not guarantee response to HER2-targeting drugs such as trastuzumab, which is cardiotoxic and expensive, so early detection of response status is crucial. Factors influencing [(18)F]FDG incorporation in the timeframe of cell signalling down-regulation subsequent to trastuzumab treatment are investigated to provide a better understanding of the relationship between growth response and modulation of [(18)F]FDG incorporation. HER-2-overexpressing breast tumour cell lines, MDA-MB-453, SKBr3 and BT474 and MDA-MB-468 (HER2 non-over-expressor) were treated with trastuzumab (4 h) and probed for AKT, pAKT, ERK1/2, pERK1/2 and HIF-1α to determine early signalling pathway inhibitory effects of trastuzumab. Cells incubated with trastuzumab and/or PI3K inhibitor LY294002 and ERK1/2 inhibitor U0126 and glucose transport and [(18)F]FDG incorporation measured. Cell lines expressed AKT, pAKT, ERK1/2 and pERK1/2 but not HIF-1α. Trastuzumab treatment decreased pAkt but not pERK1/2 levels. Trastuzumab did not further inhibit AKT when maximally inhibited with LY294002. Treatment with LY294002 and trastuzumab for 4 h decreased [(18)F]FDG incorporation in BT474 and MDA-MB-453 but not SKBr3 cells. LY294002 inhibited glucose transport by each cell line, but the glucose transport rate was tenfold higher by SKBr3 cells than BT474 and MDA-MB-453 cells. AKT-induced uptake of [(18)F]FDG was found to be HIF-1α independent in breast cancer cell lines. AKT inhibition level and tumour cell glucose transport rate can influence whether or not PI3K inhibitors affect [(18)F]FDG incorporation which may account for the variation in preclinical and clinical findings associated with [(18)F]FDG-PET in response to trastuzumab and other HER-2 targeting drugs.
AB - HER-2 overexpression does not guarantee response to HER2-targeting drugs such as trastuzumab, which is cardiotoxic and expensive, so early detection of response status is crucial. Factors influencing [(18)F]FDG incorporation in the timeframe of cell signalling down-regulation subsequent to trastuzumab treatment are investigated to provide a better understanding of the relationship between growth response and modulation of [(18)F]FDG incorporation. HER-2-overexpressing breast tumour cell lines, MDA-MB-453, SKBr3 and BT474 and MDA-MB-468 (HER2 non-over-expressor) were treated with trastuzumab (4 h) and probed for AKT, pAKT, ERK1/2, pERK1/2 and HIF-1α to determine early signalling pathway inhibitory effects of trastuzumab. Cells incubated with trastuzumab and/or PI3K inhibitor LY294002 and ERK1/2 inhibitor U0126 and glucose transport and [(18)F]FDG incorporation measured. Cell lines expressed AKT, pAKT, ERK1/2 and pERK1/2 but not HIF-1α. Trastuzumab treatment decreased pAkt but not pERK1/2 levels. Trastuzumab did not further inhibit AKT when maximally inhibited with LY294002. Treatment with LY294002 and trastuzumab for 4 h decreased [(18)F]FDG incorporation in BT474 and MDA-MB-453 but not SKBr3 cells. LY294002 inhibited glucose transport by each cell line, but the glucose transport rate was tenfold higher by SKBr3 cells than BT474 and MDA-MB-453 cells. AKT-induced uptake of [(18)F]FDG was found to be HIF-1α independent in breast cancer cell lines. AKT inhibition level and tumour cell glucose transport rate can influence whether or not PI3K inhibitors affect [(18)F]FDG incorporation which may account for the variation in preclinical and clinical findings associated with [(18)F]FDG-PET in response to trastuzumab and other HER-2 targeting drugs.
KW - [18F]FDG
KW - glucose transport
KW - PI3/AKT
KW - trastuzumab
U2 - 10.1007/s10549-014-2858-1
DO - 10.1007/s10549-014-2858-1
M3 - Article
VL - 144
SP - 241
EP - 248
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 4
ER -